REVERSE-AKI Randomized Controlled Pilot Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 8, 2017

Primary Completion Date

January 31, 2020

Study Completion Date

April 30, 2020

Conditions
Acute Kidney InjuryCritical Illness
Interventions
OTHER

Restrictive fluid management

Daily fluid input is restricted to drugs and nutrition. Fluid boluses and blood products can be given if clinically indicated. Matching fluid output to fluid input whenever possible using diuretics if needed, and additionally, if clinically necessary and plausible, commencing renal replacement therapy. If renal replacement therapy is not deemed clinically desirable, acceptance of a less than targeted fluid balance.

Trial Locations (7)

3048

Austin Hospital, Melbourne

Unknown

Canberra Hospital, Canberra

Ghent University Hospital, Ghent

Helsinki University Hospital, Helsinki

Lausanne University Hospital, Lausanne

Guy's and St Thomas Hospital, London

Royal London Hospital, Barts Health NHS Trust, London

All Listed Sponsors
collaborator

Austin Hospital, Melbourne Australia

OTHER

collaborator

Guy's and St Thomas' NHS Foundation Trust

OTHER

collaborator

University Hospital, Ghent

OTHER

collaborator

Medical University Innsbruck

OTHER

collaborator

University of Lausanne Hospitals

OTHER

lead

Helsinki University Central Hospital

OTHER

NCT03251131 - REVERSE-AKI Randomized Controlled Pilot Trial | Biotech Hunter | Biotech Hunter